These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

266 related items for PubMed ID: 16191075

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Therapeutic equivalence, long-term efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis.
    Haag-Weber M, Vetter A, Thyroff-Friesinger U, INJ-Study Group.
    Clin Nephrol; 2009 Nov; 72(5):380-90. PubMed ID: 19863881
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin.
    Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA.
    N Engl J Med; 1998 Aug 27; 339(9):584-90. PubMed ID: 9718377
    [Abstract] [Full Text] [Related]

  • 12. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
    Voravud N, Sriuranpong V, Suwanrusme H.
    J Med Assoc Thai; 2007 Jun 27; 90(6):1082-8. PubMed ID: 17624200
    [Abstract] [Full Text] [Related]

  • 13. The evaluation of postdialysis L-carnitine administration and its effect on weekly requiring doses of rHuEPO in hemodialysis patients.
    Kadiroglu AK, Yilmaz ME, Sit D, Kara IH, Isikoglu B.
    Ren Fail; 2005 Jun 27; 27(4):367-72. PubMed ID: 16060121
    [Abstract] [Full Text] [Related]

  • 14. Iron-replete hemodialysis patients do not require higher EPO dosages when converting from subcutaneous to intravenous administration: results of the Italian Study on Erythropoietin Converting (ISEC).
    Pizzarelli F, David S, Sala P, Icardi A, Casani A.
    Am J Kidney Dis; 2006 Jun 27; 47(6):1027-35. PubMed ID: 16731298
    [Abstract] [Full Text] [Related]

  • 15. Association between hematocrit level and mortality in hemodialysis patients. Case study of the anemic patient.
    Collins A, Ellefson J.
    Nephrol Nurs J; 2000 Apr 27; 27(2):233-6. PubMed ID: 11111551
    [Abstract] [Full Text] [Related]

  • 16. Is early treatment of anaemia with epoetin-alpha beneficial to pre-dialysis chronic kidney disease patients? Results of a multicentre, open-label, prospective, randomized, comparative group trial.
    Macdougall IC, Temple RM, Kwan JT.
    Nephrol Dial Transplant; 2007 Mar 27; 22(3):784-93. PubMed ID: 16968726
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Comparison of the therapeutic efficacy of epoetin beta and epoetin alfa in maintenance phase hemodialysis patients.
    Loughnan A, Ali GR, Abeygunasekara SC.
    Ren Fail; 2011 Mar 27; 33(3):373-5. PubMed ID: 21401367
    [Abstract] [Full Text] [Related]

  • 20. Results of the European Survey on Anaemia Management 2003 (ESAM 2003): current status of anaemia management in dialysis patients, factors affecting epoetin dosage and changes in anaemia management over the last 5 years.
    Jacobs C, Frei D, Perkins AC.
    Nephrol Dial Transplant; 2005 May 27; 20 Suppl 3():iii3-24. PubMed ID: 15824128
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.